About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Phf6em1Wencc
endonuclease-mediated mutation 1, Wen-Chien Chou
MGI:7280677
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Phf6em1Wencc/Phf6em1Wencc
Tg(Vav1-cre)#Cgp/0
Not Specified MGI:7280785
cn2
Phf6em1Wencc/Y
Tg(Vav1-cre)#Cgp/0
Not Specified MGI:7280786


Genotype
MGI:7280785
cn1
Allelic
Composition
Phf6em1Wencc/Phf6em1Wencc
Tg(Vav1-cre)#Cgp/0
Genetic
Background
Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Phf6em1Wencc mutation (0 available); any Phf6 mutation (12 available)
Tg(Vav1-cre)#Cgp mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• normal spleen and thymus weight and histology at age 8-12 weeks
• normal percentage of B cells in spleen at age 8-12 weeks
• normal total, naive regulatory and effector T cell function in cytokine stimulation assays at age 8-12 weeks
• normal number of B cells in bone marrow other than pro-B cells at age 8-12 weeks
• normal number of long-term hematopoietic stem cells (LT-HSCs) in bone marrow at age 8-12 weeks
• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks
• at age 18 months
• normal spleen weight and histology at age 8-12 weeks
• in bone marrow at age 8-12 weeks
• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen at age 8-12 weeks
• in blood at age 18 months
• reduced in thymus at age 8-12 weeks
• at age 8-12 weeks
• normal percentage in spleen at age 8-12 weeks
• at age 8-12 weeks
• reduced percentage in spleen at age 8-12 weeks
• more B220+ cells at ages 8-12 weeks and 18 months
• normal percentage of B cells in spleen at age 8-12 weeks
• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells in spleen at age 8-12 weeks
• reduced percentage of T cells at age 8-12 weeks
• reduced percentage of CD8+ T cells at ages 8-12 weeks and 18 months
• increased percentage of CD4+ T cells at age 18 months
• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells at ages 8-12 weeks and 18 months
• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen ages 8-12 weeks and 18 months
• normal percentage of CD4+ T cells at age 8-12 weeks
• normal percentage of B cells at age 8-12 weeks

hematopoietic system
• reduced number of type 2 and 3 multi-potent progenitor cells (MMP2s, MPP3s), LSK and long-term hematopoietic stem cells (LT-HSCs) in G0 cell cycle phase in bone marrow at age 8-12 weeks
• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks
• at age 18 months
• normal spleen weight and histology at age 8-12 weeks
• in bone marrow at age 8-12 weeks
• in spleen red pulp at age 18 months
• reduced number of LK and Lin- cells at age 8-12 weeks
• increased number of type 2 multi-potent progenitor cells (MPP2s) at age 8-12 weeks
• in bone marrow at age 8-12 weeks
• hyper- and dysplastic, smaller and with hypolobulated nuclei in bone marrow at age 18 months
• hyperplastic in bone marrow at age 18 months
• in blood at age 18 months
• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen at age 8-12 weeks
• in blood at age 18 months
• reduced in thymus at age 8-12 weeks
• at age 8-12 weeks
• normal percentage in spleen at age 8-12 weeks
• at age 8-12 weeks
• reduced percentage in spleen at age 8-12 weeks
• more B220+ cells at ages 8-12 weeks and 18 months
• normal percentage of B cells in spleen at age 8-12 weeks
• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells in spleen at age 8-12 weeks
• reduced number of long-term hematopoietic stem cells (LT-HSCs) in bone marrow at age 18 months
• in bone marrow at age 8-12 weeks
• reduced percentage of T cells at age 8-12 weeks
• reduced percentage of CD8+ T cells at ages 8-12 weeks and 18 months
• increased percentage of CD4+ T cells at age 18 months
• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells at ages 8-12 weeks and 18 months
• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen ages 8-12 weeks and 18 months
• normal percentage of CD4+ T cells at age 8-12 weeks
• normal percentage of B cells at age 8-12 weeks

endocrine/exocrine glands
• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks

growth/size/body
• at age 18 months
• normal spleen weight and histology at age 8-12 weeks

cellular
• reduced number of type 2 and 3 multi-potent progenitor cells (MMP2s, MPP3s), LSK and long-term hematopoietic stem cells (LT-HSCs) in G0 cell cycle phase in bone marrow at age 8-12 weeks

skeleton
N
• normal bone marrow cellularity and architecture at ages 8-12 weeks and 18 months




Genotype
MGI:7280786
cn2
Allelic
Composition
Phf6em1Wencc/Y
Tg(Vav1-cre)#Cgp/0
Genetic
Background
Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Phf6em1Wencc mutation (0 available); any Phf6 mutation (12 available)
Tg(Vav1-cre)#Cgp mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• reduced number of type 2 and 3 multi-potent progenitor cells (MMP2s, MPP3s), LSK and long-term hematopoietic stem cells (LT-HSCs) in G0 cell cycle phase in bone marrow at age 8-12 weeks

endocrine/exocrine glands
• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks

growth/size/body
• at age 18 months
• normal spleen weight and histology at age 8-12 weeks

hematopoietic system
N
• normal white blood cell count (WBC) at age 8 weeks
• reduced number of type 2 and 3 multi-potent progenitor cells (MMP2s, MPP3s), LSK and long-term hematopoietic stem cells (LT-HSCs) in G0 cell cycle phase in bone marrow at age 8-12 weeks
• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks
• at age 18 months
• normal spleen weight and histology at age 8-12 weeks
• in bone marrow at age 8-12 weeks
• in spleen red pulp at age 18 months
• reduced number of LK and Lin- cells at age 8-12 weeks
• increased number of type 2 multi-potent progenitor cells (MPP2s) at age 8-12 weeks
• in bone marrow at age 8-12 weeks
• hyper- and dysplastic, smaller and with hypolobulated nuclei in bone marrow at age 18 months
• hyperplastic in bone marrow at age 18 months
• in blood at age 18 months
• more B220+ cells at ages 8-12 weeks and 18 months
• normal percentage of B cells in spleen at age 8-12 weeks
• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells in spleen at age 8-12 weeks
• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen at age 8-12 weeks
• in blood at age 18 months
• reduced in thymus at age 8-12 weeks
• at age 8-12 weeks and in spleen at age 18 months
• normal percentage in spleen at age 8-12 weeks
• at age 8-12 weeks and in spleen at age 18 months
• reduced percentage in spleen at age 8-12 weeks
• reduced number of long-term hematopoietic stem cells (LT-HSCs) in bone marrow at age 18 months
• in bone marrow at age 8-12 weeks
• reduced percentage of T cells at age 8-12 weeks
• reduced percentage of CD8+ T cells at ages 8-12 weeks and 18 months
• increased percentage of CD4+ T cells at age 18 months
• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells at ages 8-12 weeks and 18 months
• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen ages 8-12 weeks and 18 months
• normal percentage of CD4+ T cells at age 8-12 weeks
• normal percentage of B cells at age 8-12 weeks

immune system
N
• normal spleen and thymus weight and histology at age 8-12 weeks
• normal percentage of B cells in spleen at age 8-12 weeks
• normal total, naive regulatory and effector T cell function in cytokine stimulation assays at age 8-12 weeks
• normal number of B cells in bone marrow other than pro-B cells at age 8-12 weeks
• normal number of long-term hematopoietic stem cells (LT-HSCs) in bone marrow at age 8-12 weeks
• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks
• at age 18 months
• normal spleen weight and histology at age 8-12 weeks
• in bone marrow at age 8-12 weeks
• more B220+ cells at ages 8-12 weeks and 18 months
• normal percentage of B cells in spleen at age 8-12 weeks
• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells in spleen at age 8-12 weeks
• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen at age 8-12 weeks
• in blood at age 18 months
• reduced in thymus at age 8-12 weeks
• at age 8-12 weeks and in spleen at age 18 months
• normal percentage in spleen at age 8-12 weeks
• at age 8-12 weeks and in spleen at age 18 months
• reduced percentage in spleen at age 8-12 weeks
• reduced percentage of T cells at age 8-12 weeks
• reduced percentage of CD8+ T cells at ages 8-12 weeks and 18 months
• increased percentage of CD4+ T cells at age 18 months
• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells at ages 8-12 weeks and 18 months
• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen ages 8-12 weeks and 18 months
• normal percentage of CD4+ T cells at age 8-12 weeks
• normal percentage of B cells at age 8-12 weeks

skeleton
N
• normal bone marrow cellularity and architecture at ages 8-12 weeks and 18 months





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
12/10/2024
MGI 6.24
The Jackson Laboratory